Clicky

Oncotelic Therapeutics, Inc(OTLC)

Description: Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.


Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Drugs Acute Myeloid Leukemia Antineoplastic Drugs Pancreatic Cancer Glioblastoma Treatment Of Acute Myeloid Leukemia Bemcentinib Severe Acute Respiratory Syndrome Devimistat

Home Page: www.oncotelic.com

29397 Agoura Road
Agoura Hills, CA 91301
United States
Phone: 650 635 7000


Officers

Name Title
Dr. Vuong Trieu Ph.D. Chairman & CEO
Mr. Amit Shah Chief Financial Officer
Dr. Chulho Park Ph.D. Consultant
Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D. Chief Clinical Officer of Translational Medicine & Director
Mr. Saranjit Saund CBO & GM of AI Division
Dr. Larn Hwang Chief Scientific Officer
Dr. Fatih M. Uckun M.D., Ph.D. Chief Medical Officer
Dr. Seymour Howard Fein M.D. Chief Regulatory Officer
Mr. Burcak Beser CTO of AI Division

Exchange: OTCQB

Country: US

Currency: US Dollar ($)

Forward PE: 4.0258
Trailing PE: 2.95
Price-to-Book MRQ: 0.8894
Price-to-Sales TTM: 8.396
IPO Date:
Fiscal Year End: December
Full Time Employees: 16
Back to stocks